Interim efficacy analysis of the phase 2 dose de-escalation trial of stereotactic arrhythmia radioablation for ventricular tachycardia (StAR-VT)

Back

EHRA Premium Access

Interim efficacy analysis of the phase 2 dose de-escalation trial of stereotactic arrhythmia radioablation for ventricular tachycardia (StAR-VT)

Session: Poster session 2: arrhythmia mechanisms, device therapy, and ventricular arrhythmias

Topic: Radiotherapy

Speaker: Doctor D. Ranganathan (Montreal, CA)

Event: EHRA 2025

Congress Presentation

Add to my library

About the speaker

Doctor Deepti Ranganathan

McGill University Health Centre, Montreal (Canada)

0 follower

146 more presentations in this session

Impact of ICD and CRT-D implantation on survival in ischemic and non-ischemic cardiomyopathy: a single-center croatian retrospective cohort study and comparative insights with the DANISH trial

Speaker: Assistant Professor M. Puljevic (Zagreb, HR)

Access

Abstract

Do the longer leadless pacemakers with helix screws affect tricuspid regurgitation after pacemaker implantation?

Access

Classification of atrial fibrillation burden pattern in cardiac implantable electronic devices

Speaker: Mr S. Majumder (Minneapolis, US)

Life-threatening arrhythmia in patients with suspected acute myocarditis

Speaker: Miss K. Bulatova (Basel, CH)

Early outcomes of left bundle branch area pacing upgrade in pediatric pacing-induced cardiomyopathy

Speaker: Mr Y. Turubayev (Astana, KZ)

Access the full session

Poster session 2: arrhythmia mechanisms, device therapy, and ventricular arrhythmias

Speakers: Doctor D. Ranganathan, Assistant Professor M. Puljevic, Mr S. Majumder, Miss K. Bulatova, Mr Y. Turubayev

Access

About the event

EHRA 2025

30 March - 1 April 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources